Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:35:43.208Z.
Consensus retrieved: 2026-10-06T09:21:00.216Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:35:43.208Z.
Quote observation: 2026-10-06T17:35:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa76e0b4cf372acfd55719bf770982f56833f7348901d63cf8ce2fa77c35bda7
Forward PE Ratio (N/A) = Dated Quote Price ($7.99) / Consensus Forward EPS ($-2.29)
FORWARD PE RATIO
N/A
BioCryst Pharmaceuticals, Inc.
Market Cap
$2.03B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.03B | N/A |
| Progyny, Inc. (PGNY)vs › | $2.04B | 20.22 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.04B | 25.53 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 16.56 |
| Alvotech (ALVO)vs › | $2.05B | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 57.20 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.09B | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 82.53 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.95B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.29 | $-2.42 – $-2.13 | 5 | n/m |
| 2027-12-31 | $0.58 | $0.34 – $0.75 | 5 | 13.8x |
| 2028-12-31 | $0.65 | $0.21 – $1.13 | 7 | 12.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
